drugset / Trial / NCT05739409
LILRB4 STAR-T Cell Therapy for Monocytic Leukemia
NaSingle-groupOpen-labelTreatment
Summary
This is a single-center,single-arm,open-label phase I clinical study to determine the safety and efficacy of LILRB4 STAR-T cells in Monocytic Leukemia subjects.
Timeline
- Start
- 2023-02-16
- Primary completion
- 2023-05-09
- Completion
- 2023-05-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LILRB4 STAR-T cells | Cell therapy | 300000 cells/kg | Intravenous |
| Subject | LILRB4 STAR-T cells | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | LILRB4 STAR-T cells | Cell therapy | 3e+06 cells/kg | Intravenous |
| Subject | LILRB4 STAR-T cells | Cell therapy | 6e+06 cells/kg | Intravenous |
| Subject | LILRB4 STAR-T cells | Cell therapy | 1e+07 cells/kg | Intravenous |